John Maraganore

Venture Partner at ARCH Venture Partners

Overview

John Maraganore holds the position of Venture Partner at ARCH Venture Partners [1]. Maraganore was born in Chicago, Illinois in 1962 to Greek immigrant parents and earned a B.A. (1984), M.S. (1985), and Ph.D. (1986) from the University of Chicago in the Division of Biological Sciences [2]. Early career positions included post-doctoral research scientist at Upjohn (1985–86) and senior scientist at Zymogenetics (1986–87), followed by a decade at Biogen in Cambridge, Massachusetts beginning in 1987, where Maraganore invented bivalirudin, a direct-acting thrombin inhibitor later commercialized as ANGIOMAX [2]. Current roles include Co-Chief Executive Officer at Corsera Health [3], Executive Chair at City Therapeutics [6], Venture Partner at Omega Funds [7], and board positions at Takeda [8], Kymera Therapeutics [9], Merida Biosciences [4], and Chairperson of the Board at Hemab Therapeutics [10].

Profile introduction
Source excerptLinkedIn [2]

John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. He has a B.A. (1984), M.S. (1985), and Ph.D. (1986) from the University of Chicago in the Division of Biological Sciences. Maraganore started his career as a post-doctoral research scientist at Upjohn from 1985-86. From 1986-87, he was a senior scientist at Zymogenetics. From 1987-1997, he was at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a direct-acting thrombin inhibitor, later commercialized in the U.S. as ANGIOMAXTM. In 1997, Maraganore joined Millennium Pharmaceuticals in a number o…

Career history

  1. Co-Chief Executive OfficerSep 2025 to presentCorsera Health
  2. Board MemberApr 2025 to presentMerida Biosciences
  3. Senior Business AdvisorNov 2024 to presentJEFFRIES FINANCIAL SERVICES LTD
  4. Executive ChairAug 2023 to presentCity Therapeutics
  5. Venture PartnerSep 2022 to presentOmega Funds
  6. Board MemberJun 2022 to presentTakeda
  7. Board MemberMar 2022 to presentKymera Therapeutics
  8. Chairperson of the BoardMar 2022 to presentHemab Therapeutics
  9. Venture PartnerARCH Venture Partners

Education

  1. Ph.D. , Department of Biochemistry and Molecular Biology1986University of Chicago
  2. M.S., Department of Biochemistry and Molecular Biology1985University of Chicago
  3. B.A., Division of Biological Sciences1984University of Chicago

This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.